LDL-cholesterol control in the primary prevention of cardiovascular diseases: An expert opinion for clinicians and health professionals

Poli A, Catapano AL,  Corsini A, et al.
Nutr Metab Cardiovasc Dis. 2023;33(2):245-257.

Frias J, Chien J, Zhang Q, et al.
Lancet Diabetes Endocrinol. Pub. online 6 Feb 2023.

Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial

Feig DS, Sanchez JJ, Murphy KE, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00004-9.

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Laffel LM, Danne T, Klingensmith GJ, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(22)00387-4.

Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels

D’Andrea E, Wexler DJ, Kim SC, et al.
JAMA Intern Med. Pub. online 6 Feb 2023.

Association of elevated arterial stiffness with cardiac target organ damage and cardiac autonomic neuropathy in young adults with diabetes: the SEARCH for diabetes in youth study

Urbina EM, Isom S, Dabelea D, et al.
Diabetes Care. 2023;dc221703.

The association of diabetes status and bone mineral density among US adults: evidence from NHANES 2005–2018

Liu B, Liu J, Pan J, et al.
BMC Endocr Disord. 2023;23(1):27.

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies

Zheng D, Li N, Hou R, et al.
BMC Med. 2023 Feb 3;21(1):40

Expert Guidance on Off-Label Use of Hybrid-Closed Loop Therapy in Pregnancies Complicated by Diabetes

Szmuilowicz E, Levy C, Buschur E, Polsky S
Diabetes Technol Ther. Pub. online 1 Feb 2023.

Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality

Persson S, Nilsson K, Karlsdotter K, et al.
Diabetes Obes Metab. 2023;25(3):726-734.